Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing
Appelbaum, Jacob, Price, April E, Oda, Kaori, Zhang, Joy, Leung, Wai-Hang, Tampella, Giacomo, Xia, Dong, So, Pauline Pl, Hilton, Sarah K, Evandy, Claudya, Sarkar, Semanti, Martin, Unja, Krostag, Anne-Rachel, Leonardi, Marissa, Zak, Daniel E, Logan, Rachael, Lewis, Paula, Franke-Welch, Secil, Ngwenyama, Njabulo, Fitzgerald, Michael, Tulberg, Niklas, Rawlings-Rhea, Stephanie, Gardner, Rebecca A, Jones, Kyle, Sanabria, Angelica, Crago, William, Timmer, John, Hollands, Andrew, Eckelman, Brendan, Bilic, Sanela, Woodworth, Jim, Lamble, Adam, Gregory, Philip D, Jarjour, Jordan, Pogson, Mark, Gustafson, Joshua A, Astrakhan, Alexander, Jensen, Michael C
Published in The Journal of clinical investigation (01.05.2024)
Published in The Journal of clinical investigation (01.05.2024)
Get full text
Journal Article
100 Drug-regulatable engineered T cells eliminate CD33+ and CD33ΔE2+ AML
Appelbaum, Jacob, Wai-Hang Leung, Unja Martin, Oda, Kaori, Tampella, Giacomo, Xia, Dong, Zhang, Joy, Anne-Rachael Krostag, Logan, Rachael, Evandy, Claudya, Vong, Quennie, Jones, Kyle, Timmer, John, Eckelman, Brendan, Rottman, Jim, Montt, Danielle, Peguero, Bryan, Pogson, Mark, Astrakhan, Alexander, Jarjour, Jordan, Gustafson, Joshua, Jensen, Michael
Published in Journal for immunotherapy of cancer (01.11.2020)
Published in Journal for immunotherapy of cancer (01.11.2020)
Get full text
Journal Article